The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
The Product Shortage PLUS Endorsement was developed in consultation with Cell One Partners Inc., a world leader in helping cell and gene therapy companies advance and achieve growth objectives toward ...
A naturally occurring gene called Cyclin A2 (CCNA2), which turns off after birth in humans, can actually make new, functioning heart cells and help the heart repair itself from injury, including a ...
In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...
We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...
Cathy Tie, who launched her first biotech in SF's IndieBio, now leads Manhattan Genomics in controversial push to edit human ...
RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking preclinical research that supports a nearly ...
Liver cells are indispensable for research—for drug testing, to better understand diseases such as hepatitis, fatty liver, cirrhosis, or liver cancer and for development of future cell therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback